Marek has obtained his PhD at the Cold Spring Harbor Laboratory working in prof. Gregory J. Hannon lab. He was working on custom genomics approaches in the small RNA biology research. He subsequently followed with a postdoc at the University of California, Berkeley with prof. Nick Ingolia studying the regulation of translation using bioinformatics and deep learning tools.
Emerging Therapeutics Showcase; Ardigen
Ardigen is harnessing advanced AI methods for novel precision medicine. The company’s in-house datasets, together with advanced AI platforms, empower the development of effective therapies.
AI-aided rational design of cancer cell therapies
Interaction of a TCR with a target antigen and off-target toxicity are predicted with AI-assisted methods.
Rita Colwell, Johns Hopkins Bloomberg School of Public Health
Manoj Dadlani, CosmosID
Understanding mechanism of action and translating microbiome science into commercially viable therapeutics remains the biggest challenge in this emerging field. With that said, pharma and biotech across many different therapeutic indications and modalities are united in this global effort to bring novel microbiome-based therapies and diagnostics into the clinical domain. This session will include some of the most impactful and promising areas of the Microbiome field and panel discussions on the challenges for faster adoption.